Skip to main content

Table 2 Comparison of the risk of morality between APAP group and control group

From: Long-term mortality of acetaminophen poisoning: a nationwide population-based cohort study with 10-year follow-up in Taiwan

Variable

APAP group

Control group

IRR (95% CI)

p-value

 

n

Death

PY#

Rate*

n

Death

PY#

Rate*

  

All

3235

241

17,685.4

13.6

9705

94

55,497.5

1.7

8.1 (6.3–10.2)

<0.001

Age (years)

 ≤20

385

9

2276.7

4.0

1155

1

6905.8

0.1

27.3 (3.5–215.5)

0.002

 21–39

2235

119

12,768.9

9.3

6705

23

39,663.3

0.6

16.1 (10.3–25.1)

<0.001

 40–64

489

58

2259.2

25.7

1467

27

7358.4

3.7

7.0 (4.4–11.1)

<0.001

 ≥ 65

126

55

380.5

144.5

378

43

15,670.0

27.4

5.3 (3.5–7.9)

<0.001

Sex

 Male

895

121

4601.9

26.3

2685

43

14,969.4

2.9

9.2 (6.5–13.0)

<0.001

 Female

2340

120

13,083.6

9.2

7020

51

40,528.1

1.3

7.3 (5.3–10.1)

<0.001

Comorbidity†

 DM

124

37

397.6

93.1

313

23

1331.5

17.3

5.4 (3.2–9.1)

<0.001

 CAD

149

48

540.2

88.9

317

26

1346.4

19.3

4.6 (2.9–7.4)

<0.001

 Stroke

84

27

323.6

83.4

137

22

501.6

43.9

1.9 (1.1–3.3)

0.025

 HTN

248

71

912.0

77.9

666

47

2918.3

16.1

4.8 (3.3–7.0)

<0.001

 Liver disease

396

54

1691.6

31.9

952

38

4633.6

8.2

3.9 (2.6–5.9)

<0.001

 Renal disease

308

46

1338.5

34.4

633

18

3099.2

5.8

5.9 (3.4–10.2)

<0.001

 Mental Disorder

1139

106

5379.8

19.7

1409

42

6831.1

6.2

3.2 (2.2–4.6)

<0.001

 Cancer

75

28

249.1

112.4

145

13

683.1

19.0

5.9 (3.1–11.4)

<0.001

Follow up period

 0–12 months

3235

104

3042.2

34.2

9705

20

9329.4

2.1

16.0 (9.9–25.7)

<0.001

 1–2 year

2897

34

2761.6

12.3

8958

19

8576.6

2.2

5.6 (3.2–9.7)

<0.001

  ≥ 2 year

2641

103

11,881.6

8.7

8236

55

37,591.5

1.5

5.9 (4.3–8.2)

<0.001

  1. #PY, person-years. *Rate, per 1000 person-years. †Participant may have multiple comorbidities. APAP, acetaminophen; IRR, incidence rate ratio; CI, confidence interval; DM, diabetes mellitus; CAD, coronary artery disease; HTN, hypertension